Galapagos NV
Compare this stock
GLPG Stock Report Card
$
53%
Performance
Score:
75/100
GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.
Analyst Price Targets
Score:
78/100
8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.
Technicals
Score:
71/100
GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
Earnings
Score:
10/100
GLPG has missed earnings 10 times in the last 20 quarters.
Profit
Score:
40/100
Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.
Volatility
Score:
50/100
GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
Galapagos NV Summary
Nasdaq / GLPG
Healthcare
Biotechnology
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
GLPG scored highly on our reportcard. Here are some similar companies and how they performed.
